| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2017 | PAHC Phibro Animal Health Corp | Bendheim Jack52 | President And CEO | Sell | 48,000 | $34.82 | $1,671,518.15 | -15.8% | |
| Jun 15, 2017 | PAHC Phibro Animal Health Corp | Bfi Co., LLC | 10% Owner | Sell | 48,000 | $34.82 | $1,671,518.15 | -15.8% | |
| Jun 12, 2017 | LLY Eli Lilly & Co | Barnes Melissa S | Chief Eth/ Cmpl Ofcr &SVP, Erm | Sell | 1,900 | $80.78 | $153,482.00 | -11.9% | |
| Jun 12, 2017 | LNTH Lantheus Holdings, Inc. | Duffy Michael P | See Remarks | Sell | 20,000 | $15.42 | $308,400.00 | -10.6% | |
| Jun 12, 2017 | LNTH Lantheus Holdings, Inc. | Heino Mary Anne50 | President &CEO | Sell | 10,000 | $15.39 | $153,900.00 | -1.6% | |
| Jun 12, 2017 | EGRX Eagle Pharmaceuticals, Inc. | Meyers Pete A. | Chief Financial Officer | Buy | 350 | $71.49 | $25,020.77 | New | |
| Jun 9, 2017 | LLY Eli Lilly & Co | Harrington Michael J | Senior VP And General Counsel | Sell | 22,833 | $79.97 | $1,825,955.01 | -26.9% | |
| Jun 9, 2017 | AMPH Amphastar Pharmaceuticals, Inc. | Prins Richard K61 | Director | Sell | 10,000 | $17.07 | $170,707.00 | -25.7% | |
| Jun 9, 2017 | PAHC Phibro Animal Health Corp | Bfi Co., LLC | 10% Owner | Sell | 48,000 | $35.62 | $1,709,920.00 | -20.0% | |
| Jun 9, 2017 | PAHC Phibro Animal Health Corp | Bendheim Jack52 | President And CEO | Sell | 48,000 | $35.62 | $1,709,920.00 | -20.0% | |
| Jun 8, 2017 | IRWD Ironwood Pharmaceuticals Inc | Olanoff Lawrence S | Director | Sell | 3,200 | $17.78 | $56,896.00 | -8.3% | |
| Jun 8, 2017 | ALKS Alkermes Plc. | Cooke Shane62 | President, Alkermes Plc | Sell | 10,000 | $60.33 | $603,333.00 | -11.8% | |
| Jun 8, 2017 | LNTH Lantheus Holdings, Inc. | Leno Sam R | Director | Sell | 15,033 | $16.33 | $245,488.89 | -27.2% | |
| Jun 8, 2017 | ALKS Alkermes Plc. | Stejbach Mark | Svp/ Chief Comm Off, Alks Inc | Sell | 10,000 | $60.34 | $603,352.00 | -18.5% | |
| Jun 8, 2017 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Sell | 700 | $22.00 | $15,400.00 | - | |
| Jun 7, 2017 | PCRX Pacira Biosciences, Inc. | Riker Lauren Bullaro76 | Vice President, Finance | Sell | 1,119 | $44.37 | $49,650.03 | -13.7% | |
| Jun 7, 2017 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Sell | 12,114 | $22.63 | $274,160.22 | -0.3% | |
| Jun 5, 2017 | PCRX Pacira Biosciences, Inc. | Jones James B | SVP &Chief Medical Officer | Sell | 767 | $43.32 | $33,227.21 | -7.2% | |
| Jun 5, 2017 | PCRX Pacira Biosciences, Inc. | Riker Lauren Bullaro76 | Vice President, Finance | Sell | 601 | $43.32 | $26,035.92 | -6.8% | |
| Jun 5, 2017 | PCRX Pacira Biosciences, Inc. | Williams Kristen Marie76 | CAO And General Counsel | Sell | 1,877 | $43.32 | $81,313.52 | -12.0% | |
| Jun 5, 2017 | PCRX Pacira Biosciences, Inc. | Braunstein Scott | SVP, Strategy &Corp. Dev. | Sell | 768 | $43.32 | $33,270.53 | -7.1% | |
| Jun 5, 2017 | PCRX Pacira Biosciences, Inc. | Stack David M67 | CEO And Chairman | Sell | 4,311 | $43.32 | $186,756.83 | -6.7% | |
| Jun 5, 2017 | PCRX Pacira Biosciences, Inc. | Scibetta James S | President | Sell | 1,966 | $43.32 | $85,169.09 | -7.3% | |
| Jun 5, 2017 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Sell | 19,647 | $23.38 | $459,437.09 | -0.4% | |
| Jun 2, 2017 | SNY Sanofi | Sanofi | 10% Owner | Buy | 136,050 | $478.17 | $65,055,558.00 | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.